FDA May Ask Circulatory Panel To Revisit AF Burden Definition, CryoCor Says
This article was originally published in The Gray Sheet
Executive Summary
The CryoCor cardiac cryoablation system will be the first FDA-approved device for treating paroxysmal (episodic) atrial fibrillation by ablating the pulmonary vein ostia, the source of about one-third of all AF, according to San Diego developer CryoCor